Ember LifeSciences Inc., a provider of cold chain technology, has appointed Ann Hyllengren as Chief Financial Officer to support the company’s next phase of growth.

“We are thrilled to welcome Ann at a pivotal stage in our evolution,” said Clay Alexander, founder and CEO of Ember LifeSciences. “She brings deep financial and operational leadership experience at one of the top life science companies in the world and will be instrumental as we develop and launch new reliable, sustainable cold chain solutions for life sciences, and beyond.”

About Ann Hyllengren

Hyllengren joins Ember LifeSciences from Amgen, where she brings nearly two decades of experience across global accounting and finance, capital planning and investor relations.

Most recently, she served as a senior executive on Amgen’s Investor Relations team, partnering closely with executive leadership to oversee capital markets engagement and translate complex financial performance into a clear, compelling narrative for investors. She also held multiple senior finance leadership roles at Amgen, including serving as head of finance for the U.S. General Medicine business unit, where she delivered insights to inform product strategy, resource allocation and profitability. In addition, she led the management of a $1 billion annual capital portfolio and served as Chief Financial Officer of the Amgen Foundation, overseeing initiatives supporting STEM education and community investment.

Prior to joining Amgen, Hyllengren worked in external reporting at Dole Food Company and began her career in assurance and business advisory services at PricewaterhouseCoopers LLP. She also served as an adjunct professor at Moorpark College and the University of La Verne.

Hyllengren is an active Certified Public Accountant and holds a Master of Accounting from the University of Southern California and a Bachelor of Arts in Business Management Economics from the University of California, Santa Cruz.

“I am excited to join a team that is working to solve one of the healthcare industry’s most costly challenges, with a clear focus on sustainability and improving patient outcomes,” said Hyllengren. “Ember is creating a disruptive and positive impact across the life sciences supply chain, and I look forward to supporting the company’s operational scale and market expansion.”